Breast Cancer Therapy
New breast cancer therapy research from Endocrinology and Metabolic Medicine and Sterix Ltd. outlined
Published in Hospital Business Week, February 4th, 2007
Data detailed in "In vivo efficacy of STX213, a second-generation steroid sulfatase inhibitor, for hormone-dependent breast cancer therapy" have been presented. "Steroid sulfatase (STS) inhibitors that can decrease or prevent the biosynthesis of estrogenic steroids via the sulfatase route may play an important role in the treatment of breast cancer. We compare the in vivo efficacy of two potent STS inhibitors, STX64 and STX213, in a xenograft breast cancer model," scientists writing in the journal Clinical Cancer Research report.
"MCF-7 cells stably expressing STS cDNA (MCF-7STS) were generated. Ovariectomized MF-1 female nude mice receiving s.c. injections of...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hospital Business Week
More Articles from Hospital Business Week
- Awards
Cardiocom awarded three Consumer Health World Awards - Awards
Crutchfield Dermatology wins website award for 'Best Healthcare Content' - Awards
QuadraMed earns Best in KLAS Award in 2006 KLAS Year-End Report - Biliary Cancer
Pro-Pharmaceuticals signs agreement to expand recruitment in Germany for biliary cancer trial - Business & Finance
Avitar reports loss of $0.80 per share - Business Update
Abu Dhabi health authorities deny permission for use of Mologen's cell-based gene therapy - More from this issue of Hospital Business Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
